Amgen (NASDAQ: AMGN) expands TrumpRx pricing deal, offers Aimovig and Amjevita at $299

Amgen Inc. (NASDAQ: AMGN) on December 19, 2025, expanded its direct-to-patient pricing strategy and confirmed compliance with the Trump Administration’s Most Favored Nation pricing initiative, extending steep discounts to Aimovig and Amjevita under its AmgenNow program. The move, which also integrates all three discounted drugs into the TrumpRx.gov platform, aligns with policy commitments laid out in President Donald Trump’s July 31, 2025, letter to the pharmaceutical industry.

The pricing changes build on Amgen’s earlier discount on Repatha, added to AmgenNow in October 2025, and position the company as one of the earliest and most proactive participants in the TrumpRx initiative. In exchange, Amgen is receiving relief from industry-specific tariffs—terms that are now becoming a key component of U.S. pharma–policy negotiations.

What is the strategic rationale behind Amgen’s TrumpRx pricing alignment in December 2025?

The headline from Amgen’s December 19 disclosure is not the price cuts alone, but their strategic packaging. The company is now offering Aimovig (erenumab-aooe) and Amjevita (adalimumab-atto) directly to U.S. patients at a monthly cost of $299—representing price reductions of approximately 60 percent and 80 percent, respectively, from their list prices. These follow the October 2025 inclusion of Repatha (evolocumab) at $239 per month.

What stands out is that all three biologics are now available through both the AmgenNow platform and the federal TrumpRx.gov program. Unlike traditional access or copay programs, these channels allow for cash purchases and out-of-pocket payments by the uninsured or underinsured, bypassing intermediaries such as pharmacy benefit managers (PBMs).

In effect, Amgen is negotiating market access directly with the federal government—and doing so on terms that fulfill policy objectives while enabling the company to retain pricing flexibility outside institutional contracts. It is also setting a precedent that pricing cuts do not have to occur via blanket rebates or government-mandated ceilings, but can instead be implemented through targeted programs designed to satisfy policy optics.

How do recent investments in Ohio and North Carolina factor into Amgen’s policy alignment strategy?

Amgen’s December 2025 announcement references its prior capital commitments as part of a broader policy bargain. The company is leveraging previously disclosed expansions in Ohio and North Carolina to secure tariff exemptions from the U.S. government. These expansions, while significant on their own, are now being repositioned as compliance assets rather than standalone capex events.

In April 2025, Amgen announced a $900 million expansion to its Ohio manufacturing facility, increasing its total investment in Central Ohio to over $1.4 billion and its expected job creation to 750 roles. The site, first greenlit in 2021, serves as a flagship for Amgen’s domestic drug substance manufacturing footprint.

Earlier, in December 2024, the company committed $1 billion toward a second facility at its Holly Springs, North Carolina campus, lifting its total planned investment in that state to $1.5 billion. The North Carolina hub is being designed as a sustainability-forward, next-generation biomanufacturing complex that will add 370 new jobs and bolster Amgen’s global supply network.

By bundling these investments into its pricing compliance narrative, Amgen is effectively trading capital expenditures for regulatory goodwill—a dynamic that may redefine how the biopharma sector interacts with U.S. industrial policy under the Trump administration.

Why is Amgen’s pricing strategy significant for the broader pharmaceutical market?

This is not just about Amgen cutting prices—it is about how, why, and where it is doing so. Unlike firms that oppose the government’s Most Favored Nation pricing framework or seek legal recourse, Amgen is building a proactive compliance model that protects its innovation pipeline while avoiding blanket exposure to federal enforcement.

The use of direct-to-patient pricing through AmgenNow allows the company to control distribution channels, manage margin leakage, and optimize public sentiment. Integrating the same offerings with TrumpRx.gov adds political capital without entirely surrendering pricing power across payer segments.

This dual-channel structure may now become the template for other biopharma players seeking to appease federal pricing mandates without compromising their business models. Amgen’s ability to balance compliance with control puts pressure on its peers to either replicate the approach or risk regulatory disadvantage.

What role do tax incentives and industrial policy play in Amgen’s positioning?

Amgen is explicitly crediting the Tax Cuts and Jobs Act of 2017 and the more recent One Big Beautiful Bill Act of 2025 as enablers of its U.S. manufacturing investments. These laws, designed to repatriate capital and stimulate domestic infrastructure development, have made it economically viable for Amgen to expand its U.S. operations while still investing heavily in R&D.

Since 2018, the company says it has invested more than $40 billion in manufacturing and research and development, with nearly $5 billion in direct U.S. capital expenditures post-TCJA. It estimates this has generated over $12 billion in downstream U.S. economic output.

But Amgen is not merely citing these numbers to validate its business case. It is using them as political currency—anchoring its drug pricing cooperation in the broader context of economic patriotism. This approach is positioning Amgen as both a pharmaceutical innovator and a strategic industrial partner.

Are other drugmakers likely to follow Amgen’s lead under TrumpRx?

Amgen’s actions may represent a fork in the road for large-cap biopharma. While some companies continue to fight pricing mandates through legal channels or lobbying, Amgen is choosing to negotiate on the basis of value creation—both clinical and industrial.

If tariff relief and reputational insulation are available in exchange for drug discounts and domestic production, other firms may seek similar deals. Especially for companies with strong biologics portfolios and U.S. facilities, the economics of alignment may now outweigh the optics of defiance.

That said, not all firms will be able to replicate Amgen’s operational footprint or control over manufacturing. For contract-heavy or small-molecule–focused companies, the calculus is very different. Amgen’s first-mover advantage here is structural, not just strategic.

What are the risks and unknowns in Amgen’s new compliance model?

While the model appears effective, it is not without risk. Discounted pricing through AmgenNow could raise questions among commercial payers, especially if the federal cash price undercuts insurer-negotiated rates. There is also the possibility of political turnover or policy shifts that unwind TrumpRx’s incentives or invalidate negotiated tariff relief.

Furthermore, by setting a pricing precedent, Amgen could face pressure to extend similar discounts to other therapies, particularly if patient advocacy groups or state agencies begin to cite the $299 price point as a fairness benchmark.

However, these risks are moderated by the company’s careful choice of therapies—biologics that are high-value but not universally prescribed, and thus less likely to trigger widespread reimbursement friction.

Key takeaways on what Amgen’s December 2025 pricing and policy alignment means for the industry

• Amgen extended AmgenNow to include Aimovig and Amjevita at $299/month, joining Repatha, which was added in October 2025 at $239/month.

• All three drugs are now available through TrumpRx.gov, meeting Most Favored Nation pricing terms from President Trump’s July 31 letter.

• The company confirmed these pricing concessions are linked to prior U.S. investments, notably expansions in Ohio and North Carolina.

• In April 2025, Amgen announced an additional $900 million investment in Ohio, bringing its total there to $1.4 billion.

• In December 2024, Amgen revealed a $1 billion second facility in North Carolina, lifting total investment in Holly Springs to $1.5 billion.

• Amgen is receiving three years of tariff relief in exchange for its pricing cooperation and domestic capital deployment.

• The company is leveraging tax legislation (TCJA and One Big Beautiful Bill Act) to justify long-term U.S. investment.

• Amgen’s approach may become the new template for pharma–government cooperation under politically enforced pricing regimes.